Identification and monitoring of Copy Number Variants (CNV) in monoclonal gammopathy

References

• Furukawa Y, Kikuchi J. Molecular basis of clonal evolution in multiple myeloma. Int J Hematol. 2020;111:496–511. doi:10.1007/s12185-020-02829-6.
   PubMed Web of Science ®Google Scholar
• Mohty M, Cavo M, Fink L, Gonzalez-mcquire S, Leleu H, Mateos MV, Raab MS, Schoen P, Yong K. Understanding mortality in multiple myeloma: findings of a European retrospective chart review. Eur J Haematol. 2019;103:107–115. doi:10.1111/ejh.13264.
   PubMed Web of Science ®Google Scholar
• Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A, Rossi D, Cavalli M, Wijermans P, Ria R, et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica. 2013;98:980–987. doi:10.3324/haematol.2012.075051.
   PubMed Web of Science ®Google Scholar
• Vacca A, Melaccio A, Sportelli A, Solimando AG, Dammacco F, Ria R. Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial. Clin Immunol. 2018;191:110–115. doi:10.1016/j.clim.2017.11.014.
   PubMed Web of Science ®Google Scholar
• Blimark C, Holmberg E, Mellqvist UH, Landgren O, Bjorkholm M, Hultcrantz M, Kjellander C, Turesson I, Kristinsson SY. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100:107–113. doi:10.3324/haematol.2014.107714.
   PubMed Web of Science ®Google Scholar
• van Nieuwenhuijzen N, Spaan I, Raymakers R, Peperzak V. From MGUS to multiple myeloma, a paradigm for clonal evolution of premalignant cells. Cancer Res. 2018;78:2449–2456. doi:10.1158/0008-5472.CAN-17-3115.
   PubMed Web of Science ®Google Scholar
• Pérez-Persona E, Mateo G, García-Sanz R, Mateos MV, De Las Heras N, De Coca AG, Hernández JM, Galende J, Martín-Nuñez G, Bárez A, et al. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol. 2010;148:110–114. doi:10.1111/j.1365-2141.2009.07929.x.
   PubMed Web of Science ®Google Scholar
• Musto P, Pietrantuono G, Guariglia R, Villani O, Martorelli MC, D’Auria F, Zonno A, Lerose R. Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia. Leuk Res. 2008;32:1637–1638.
   PubMed Web of Science ®Google Scholar
• Da Vià MC, Solimando AG, Garitano‐Trojaola A, Barrio S, Munawar U, Strifler S, Haertle L, Rhodes N, Teufel E, Vogt C, et al. CIC mutation as a molecular mechanism of acquired resistance to combined BRAF‐MEK inhibition in extramedullary multiple myeloma with central nervous system involvement. Oncologist. 2020;25:112–118. doi:10.1634/theoncologist.2019-0356.
   PubMed Web of Science ®Google Scholar
• Frassanito MA, Desantis V, Di Marzo L, Craparotta I, Beltrame L, Marchini S, Annese T, Visino F, Arciuli M, Saltarella I, et al. Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes. J Pathol. 2019;247:241–253. doi:10.1002/path.5187.
   PubMed Web of Science ®Google Scholar
• Solimando AG, Da Vià MC, Cicco S, Leone P, Di Lernia G, Giannico D, Desantis V, Frassanito MA, Morizio A, Delgado Tascon J, et al. High-risk multiple myeloma: integrated clinical and omics approach dissects the neoplastic clone and the tumor microenvironment. J Clin Med. 2019;8:997. doi:10.3390/jcm8070997.
   Web of Science ®Google Scholar
• Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12:335–348. doi:10.1038/nrc3257.
   PubMed Web of Science ®Google Scholar
• Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, Dawson KJ, Iorio F, Nik-Zainal S, Bignell GR, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014;5:2997.
   Web of Science ®Google Scholar
• Aktas Samur A, Minvielle S, Shammas M, Fulciniti M, Magrangeas F, Richardson PG, Moreau P, Attal M, Anderson KC, Parmigiani G, et al. Deciphering the chronology of copy number alterations in Multiple Myeloma. Blood Cancer J. 2019;9(4):39.
   PubMed Web of Science ®Google Scholar
• Terragna C, Martello M, Durante S, Pantani L, Zamagni E, Tacchetti P, Brioli A, Perrone G, Zannetti BA, Borsi E, et al. High number of copy number alterations and over-expression of genes involved in the response mechanisms to genotoxic stress both characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p53. Blood. 2011;118: 3935–3935. doi:10.1182/blood.V118.21.3935.3935.
   PubMed Web of Science ®Google Scholar
• Bustoros M, Mouhieddine TH, Detappe A, Ghobrial IM. Established and novel prognostic biomarkers in Multiple Myeloma. Am Soc Clin Oncol Educ B. 2017;37:548–560. doi:10.1200/EDBK_175175.
   PubMedGoogle Scholar
• Chillón MC, Jiménez C, García-Sanz R, Alcoceba M, Prieto I, García-Alvarez M, Antón A, Maldonado R, Hernández-Ruano M, González M, et al. Quantitative PCR: an alternative approach to detect common copy number alterations in multiple myeloma. Ann Hematol. 2017;96:1699–1705. doi:10.1007/s00277-017-3083-x.
   PubMed Web of Science ®Google Scholar
• Fernando RC, de Carvalho F, Mazzotti DR, Evangelista AF, Braga WM, de Lourdes Chauffaille M, Leme AF, Colleoni GW. Multiple Myeloma Cell Lines and Primary Tumors Proteoma: Protein Biosynthesis and Immune System as Potential Therapeutic Targets. Genes Cancer. 2015;6:462.
   PubMedGoogle Scholar
• Quentmeier H, Pommerenke C, Dirks WG, Eberth S, Koeppel M, MacLeod RAF, Nagel S, Steube K, Uphoff CC, Drexler HG. panel: 100 cell lines for blood cancer studies. Sci Rep. 2019;9. DOI:10.1038/s41598-019-44491-x.
   PubMed Web of Science ®Google Scholar
• Hanamura I. Gain/amplification of chromosome arm 1q21 in multiple myeloma. Cancers (Basel). 2021;13:1–16. doi:10.3390/cancers13020256.
   Google Scholar
• Fernando RC, de Carvalho F, Mazzotti DR, Evangelista AF, Tobias Braga WM, de L Chauffaille M, Paes Leme AF, Colleoni GWB. Multiple Myeloma Cell Lines and Primary Tumors Proteome: Protein Biosynthesis and Immune System as Potential Therapeutic Targets. Genes Cancer. 2015;6:462–471.
   PubMedGoogle Scholar
• Bolli N, Biancon G, Moarii M, Gimondi S, Li Y, de Philippis C, Maura F, Sathiaseelan V, Tai YT, Mudie L, et al. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2018;32:2604–2616. doi:10.1038/s41375-018-0037-9.
   PubMed Web of Science ®Google Scholar
• Saxe D, Seo EJ, Bergeron MB, Han JY. Recent advances in cytogenetic characterization of multiple myeloma. Int J Lab Hematol. 2019;41:5–14. doi:10.1111/ijlh.12882.
   PubMed Web of Science ®Google Scholar
• Shaughnessy J, Tian E, Sawyer J, Bumm K, Landes R, Badros A, Morris C, Tricot G, Epstein J, Barlogie B. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood. 2000. doi:10.1182/blood.V96.4.1505.
   Web of Science ®Google Scholar
• Balcárková J, Urbánková H, Ščudla V, Holzerová M, Bačovský J, Indrák K, Jarošová M. Gain of chromosome arm 1q in patieznts in relapse and progression of multiple myeloma. Cancer Genet Cytogenet. 2009;192:68–72. https://www.cancergeneticsjournal.org/article/S0165-4608(09)00146-0/fulltext.
   PubMedGoogle Scholar
• An G, Xu Y, Shi L, Shizhen Z, Deng S, Xie Z, Sui W, Zhan F, Qiu L. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value. Haematologica. 2014;99:353–359. http://www.haematologica.org/content/99/2/353.long.
   PubMed Web of Science ®Google Scholar
• Schmidt TM, Barwick BG, Joseph N, Heffner LT, Hofmeister CC, Bernal L, Dhodapkar MV, Gupta VA, Jaye DL, Wu J, et al. Gain of chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood Cancer J. 2019;9. https://pubmed.ncbi.nlm.nih.gov/31767829/.
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12:335–348. http://www.nature.com/articles/nrc3257.
   PubMed Web of Science ®Google Scholar
• Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR, Hollmig K, Zangarri M, Pineda-Roman M, Van Rhee F, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantatio. Blood. 2006;108:1724–1732. doi:10.1182/blood-2006-03-009910.
   PubMed Web of Science ®Google Scholar
• Whale AS, Huggett JF, Cowen S, Speirs V, Shaw J, Ellison S, Foy CA, Scott DJ. Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation. Nucleic Acids Res. 2012;40:e82–e82. doi:10.1093/nar/gks203.
   PubMed Web of Science ®Google Scholar
• Perkins G, Lu H, Garlan F, Taly V. 2017. Droplet-based digital PCR: application in cancer research. In: Advances in clinical chemistry. Academic Press Inc; p. 43–91.
   Google Scholar
• Kanagal-Shamanna R. Digital PCR: principles and applications.Methods Mol Biol. 2016;1392:43–50. doi:10.1007/978-1-4939-3360-0_5.
   Google Scholar
• Cilloni D, Petiti J, Rosso V, Andreani G, Dragani M, Fava C, Saglio G. Digital PCR in myeloid malignancies: ready to replace quantitative PCR? Int J Mol Sci. 2019;20. DOI:10.3390/ijms20092249.
   PubMed Web of Science ®Google Scholar
• Weaver S, Dube S, Mir A, Qin J, Sun G, Ramakrishnan R, Jones RC, Livak KJ. Taking qPCR to a higher level: analysis of CNV reveals the power of high throughput qPCR to enhance quantitative resolution. Methods. 2010;50:271–276. doi:10.1016/j.ymeth.2010.01.003.
   PubMed Web of Science ®Google Scholar
• López-Corral L, Sarasquete ME, Beà S, García-Sanz R, Mateos MV, Corchete LA, Sayagués JM, García EM, Bladé J, Oriol A, et al. SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status. Leukemia. 2012;26:2521–2529. doi:10.1038/leu.2012.128.
   PubMed Web of Science ®Google Scholar
• Elnenaei MO, Hamoudi RA, Swansbury J, Gruszka-Westwood AM, Brito-Babapulle V, Matutes E, Catovsky D. Delineation of the minimal region of loss at 13q14 in multiple myeloma. Genes Chromosom Cancer. 2003;36:99–106. doi:10.1002/gcc.10140.
   PubMed Web of Science ®Google Scholar
• Rajan AM, Rajkumar SV. Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer J. 2015;5. DOI:10.1038/bcj.2015.92.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48. doi:10.1016/S1470-2045(14)70442-5.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, José Lahuerta J, Facon T, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015; 33:2863–2869.
   PubMed Web of Science ®Google Scholar
• Greipp PR, Miguel JS, Dune BGM, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Harousseau JL, Kyle RA, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–3420. doi:10.1200/JCO.2005.04.242.
   PubMed Web of Science ®Google Scholar
• Solimando AG, Da Vià MC, Leone P, Borrelli P, Croci GA, Tabares P, Brandl A, Di Lernia G, Bianchi FP, Tafuri S, et al. Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores the angiogenic homeostasis and suppresses tumor progression. Haematologica. 2021 Jul 1;106(7):1943–1956. doi:10.3324/haematol.2019.239913
   Google Scholar
• Leone P, Di Lernia G, Solimando AG, Cicco S, Saltarella I, Lamanuzzi A, Ria R, Frassanito MA, Ponzoni M, Ditonno P, et al. Bone marrow endothelial cells sustain a tumor-specific CD8+ T cell subset with suppressive function in myeloma patients. Oncoimmunology. 2019;8. DOI:10.1080/2162402X.2018.1486949.
   PubMed Web of Science ®Google Scholar
• Lamanuzzi A, Saltarella I, Desantis V, Frassanito MA, Leone P, Racanelli V, Nico B, Ribatti D, Ditonno P, Prete M, et al. Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma. Oncotarget. 2018. doi:10.18632/oncotarget.25003.
   PubMedGoogle Scholar